DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Nonstatutory Obvious-type Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg , 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman , 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi , 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum , 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel , 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington , 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). 1) Claims 1-10 are rejected on the ground of nonstatutory double patenting a s being unpatentable over claim s 1-15 of U.S. Patent No. 8,039,431 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin . 2) Claims 1-10 are rejected on the ground of nonstatutory double patenting a s being unpatentable over claims 1-25 of U.S. Patent No. 8,512,932 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin . 3 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1- 24 of U.S. Patent No. 9,241,903 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 4 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-1 4 of U.S. Patent No. 10,130,581 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 5 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1- 6 of U.S. Patent No. 10,376,466 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 6 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-1 3 of U.S. Patent No. 7,820,676 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 7 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1- 9 of U.S. Patent No. 11,192,862 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 8 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-1 1 of U.S. Patent No. 10,745,359 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 9 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1- 2 1 of U.S. Patent No. 10,421,729 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 1 0 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-1 4 of U.S. Patent No. 9,675,674 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 1 1 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-1 9 of U.S. Patent No. 10,130,685 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. 1 2 ) Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-1 9 of U.S. Patent No. 10,583,176 . Although the claims at issue are not identical, they are not patentably distinct from each other because both claim a method of making powders of diketopoperazine loaded with an active agent, e.g., insulin. Conclusion Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT WALTER E WEBB whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from FILLIN "Work schedule?" \* MERGEFORMAT Mon-Fri 7-3:30 . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana K aup can be reached (571) 272- 6897 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/ Primary Examiner, Art Unit 1612